38095
GRANULES INDIA LIMITED
Feb 17, 2017
India
South Asia
Oct 16, 2025
Completed
Approved : Mar 29, 2017
Signed : Mar 31, 2017
Invested : Apr 13, 2017
Pharmaceuticals and Medicine
Health, Education and Life Sciences
Regional Industry - MAS Asia & Pac
Granules India Limited (“Granules” or “the company”) is a 30-year-old Hyderabad-based pharmaceutical company, with world-class manufacturing facilities for active pharmaceutical ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and finished dosages (FDs) of a variety of drugs including over-the-counter ones.
The company has two API manufacturing facilities, near Hyderabad, in Telangana (Jeedimetla and Bonthapally) and one in Visakhapatnam (or Vizag) (acquired from Auctus Pharma in November 2014); a PFIs and FDs facility in Gagillapur, near Hyderabad, in Telangana; and a research and development (R&D) and manufacturing facility in United States of America (USA). Additionally, the company has two facilities under its joint ventures (JVs) – in Vizag Special Economic Zone and in Jingmen, China.
To date, IFC has made three investments in Granules:
(a) Debt and equity investment in 2007 (IFC exited the equity investment in 2014);
(b) Cleaner Production Lending Facility (CPLF) loan in 2009; and
(c) Debt investment in 2011 for capacity expansion in Gagillapur facility.
The proposed investment is IFC’s fourth investment in the company and involves a debt investment of up to US$47.5 million to part-finance Granules’ investment program directed towards setting up new capacity, expanding existing capacities; investing in other general capital expenditure requirement at all existing facilities; and investing in R&D to improve its product mix in favor of higher value-added products. A large part of the investment program is in the form of capital expenditures in India (the “Project”), which is estimated to cost about $84 million. The Project includes building a greenfield API manufacturing facility in Vishakhapatnam, India, expanding existing API and PFI capacities (including constructing a new block in Bonthapally facility), investment in R&D, quality assurance ("QA”), and quality control("QC”) and additional warehouse capacity .
This will be IFC’s fourth investment in Granules. The Environmental and Social Review Summaries (ESRSs) of the previous three investments are available here:
The company has, to this date, successfully implemented the Environmental and Social Action Plans (ESAP) action items for these investments and therefore, the existing IFC investments are currently judged to have a satisfactory rating as regards Environmental and Social Performance. The information presented in the following sections builds upon the above mentioned documents.
Considering the nature of the proposed investment (new processing plants with similar operations as some of the existing facilities and expansion with the existing facilities), this review thus, builds upon the previously disclosed ESRSs and ESAPs, and the information collected during IFC’s engagement with Granules over the past several years; and covers specific environmental, health and safety (EHS) and human resource (HR) aspects related to the new and expanded facilities.
Additionally, the IFC E&S Review of this proposed investment consisted of reviewing company information related to technical, EHS and social matters including: facility specific E&S policies, management plans and procedures, EHS monitoring reports, other management systems information (internal audits, objectives and targets, procedures), regulatory permits, safety audits, on-site emergency response plans, EHS training records and human resource (HR) related records. For the under construction facilities, proposed layouts and plans, details of utilities (e.g. diesel generators, effluent treatment plant), regulatory permits, construction safety procedures, and EHS monitoring records for the contractors were reviewed.
The appraisal also included site visits (in December 2016) to:
(a) Operational API manufacturing facilities at Jawaharlal Nehru (JN) Pharma City, in Visakhapatnam (or Vizag), in Andhra Pradesh and Bonthapally, near Hyderabad, in Telangana; and
(b) Under construction API manufacturing facility, in JN Pharma City, in Vizag.
Further, discussions were held with senior management of the facilities including General Manager - Operations (Plant Manager), EHS Head and HR Manager (at the Vizag facility); Associate Vice President (AVP) – HR and Administration, AVP – Operations, EHS Manager (at the Bonthapally facility); and corporate staff including Vice President – Manufacturing Operations and Senior Manager – EHS (responsible for Hyderabad facilities). Also, discussions were held with the Vice President – Projects and safety team of the contractor at the under construction facility.